Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Exelixis Hopes CABOSUN Means New Dawn For Cabometyx In Frontline Kidney Cancer

Executive Summary

Exelixis’s plan to file an sNDA, based on positive results in the Phase II CABOSUN study, could support an early approval for cabozantinib in first-line kidney cancer, spuring more change in the crowded kidney cancer market

Advertisement

Related Content

Keeping Track: Oncology Stays Hot With Besponsa And Lynparza Approvals; New Uses Of Adcetris, Cabometyx Submitted
Exelixis's CABOSUN Rises For Cabometyx After Bristol's Opdivo/Yervoy Letdown
NICE Move On Cabometyx Gives BMS Longer To Make Opdivo Case In Second Line RCC
Exelixis' Strong Cabometyx Start Signals Changing Of Guard In Kidney Cancer Market

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097454

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel